The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells

Molecular Pharmacology

Volumn 84, Issue 3, 2013, Pages 438-450

  Hummel Eisenbeiss, Johanna ^a,b   Hascher, Antje ^c   Hals, Petter Arnt ^d   Sandvold, Marit Liland ^d   Müller Tidow, Carsten ^c   Lyko, Frank ^a,b   Rius, Maria ^a  

^a GERMAN CANCER RESEARCH CENTER   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d Clavis Pharma   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZACYTIDINE 5' ELAIDATE; AZACITIDINE; CP 4200; CYTIDINE DERIVATIVE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; NITROBENZYLTHIOINOSINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CELL TRANSPORT; CLINICAL ARTICLE; CYTOTOXICITY; DNA METHYLATION; DOG; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOGS; DRUG RESISTANCE, NEOPLASM; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HUMANS; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; MADIN DARBY CANINE KIDNEY CELLS;

EID: 84883164791     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.086801     Document Type: Article

References (38)

1. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, and Legrand O (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10: 7896-7902.
2. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP, and Legrand O (2005) MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 11: 7764-7772.
3. Borbath I, Verbrugghe L, Lai R, Gigot JF, Humblet Y, Piessevaux H, and Sempoux C (2012) Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur J Cancer 48: 990-996.
4. Brueckner B, Rius M, Markelova MR, Fichtner I, Hals PA, Sandvold ML, and Lyko F (2010) Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy. Mol Cancer Ther 9: 1256-1264.
5. Castro F, Dirks WG, Fahnrich S, Hotz-Wagenblatt A, Pawlita M, and Schmitt M (2013) High-throughput SNP-based authentication of human cell lines. Int J Cancer 132: 308-314.
6. Egger G, Liang G, Aparicio A, and Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429: 457-463.
7. Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, and Dumontet C (2002) Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26: 621-629.
8. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236.
9. Gillet JP and Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596: 47-76.
10. Griffiths EA and Gore SD (2013) Epigenetic therapies in MDS and AML. Adv Exp Med Biol 754: 253-283.
11. Griffiths M, Beaumont N, Yao SY, Sundaram M, Boumah CE, Davies A, Kwong FY, Coe I, Cass CE, Young JD, et al. (1997) Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3: 89-93.
12. Grönniger E, Weber B, Heil O, Peters N, Stäb F, Wenck H, Korn B, Winnefeld M, and Lyko F (2010) Aging and chronic sun exposure cause distinct epigenetic changes in human skin. PLoS Genet 6:e1000971.
13. Hammond JR, Stolk M, Archer RG, and McConnell K (2004) Pharmacological analysis and molecular cloning of the canine equilibrative nucleoside transporter 1. Eur J Pharmacol 491: 9-19.
14. Issa JP (2007) DNA methylation as a therapeutic target in cancer. Clin Cancer Res 13: 1634-1637.
15. Komori S, Osada S, Mori R, Matsui S, Sanada Y, Tomita H, Tokuyama Y, Takahashi T, Yamaguchi K, and Yoshida K (2010) Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer. Pancreas 39: 1284-1292.
16. Legrand O, Zompi S, Perrot JY, Faussat AM, Benderra Z, Chaoui D, and Marie JP (2004) P-glycoprotein and multidrug resistance associated protein-1 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups. Haematologica 89: 34-41.
17. Lübbert M, Müller-Tidow C, Hofmann WK, and Koeffler HP (2008) Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapy. J Cell Biochem 104: 2059-2070.
18. Mangravite LM, Badagnani I, and Giacomini KM (2003) Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 479: 269-281.
19. Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, and Hammel P et al. (2012) Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143:664-674, e1-e6.
20. Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, and Devière J et al. (2009) Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 15: 2913-2919.
21. Paproski RJ, Visser F, Zhang J, Tackaberry T, Damaraju V, Baldwin SA, Young JD, and Cass CE (2008) Mutation of Trp29 of human equilibrative nucleoside transporter 1 alters affinity for coronary vasodilator drugs and nucleoside selectivity. Biochem J 414: 291-300.
22. Qin T, Jelinek J, Si J, Shu J, and Issa JP (2009) Mechanisms of resistance to 5-aza-29- deoxycytidine in human cancer cell lines. Blood 113: 659-667.
23. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, and Borst P (2003) Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63: 1094-1103.
24. Rius M, Keller D, Brom M, Hummel-Eisenbeiss J, Lyko F, and Keppler D (2010) Vectorial transport of nucleoside analogs from the apical to the basolateral membrane in double-transfected cells expressing the human concentrative nucleoside transporter hCNT3 and the export pump ABCC4. Drug Metab Dispos 38: 1054-1063.
25. Rius M and Lyko F (2012) Epigenetic cancer therapy: rationales, targets and drugs. Oncogene 31: 4257-4265.
26. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, and Keppler D (2003) Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38: 374-384.
27. Rius M, Stresemann C, Keller D, Brom M, Schirrmacher E, Keppler D, and Lyko F (2009) Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther 8: 225-231.
28. Sarkar M, Han T, Damaraju V, Carpenter P, Cass CE, and Agarwal RP (2005) Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Biochem Pharmacol 70: 426-432.
29. Schmitt M and Pawlita M (2009) High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res 37:e119.
30. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, and Gottesman MM (2012) Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat 15: 62-69.
31. Shan D, Haroutunian V, Meador-Woodruff JH, and McCullumsmith RE (2012) Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia. Neuroreport 23: 224-227.
32. Silverman LR (2009) Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents. Leuk Res 33 (Suppl 2):S18-S21.
33. Stach D, Schmitz OJ, Stilgenbauer S, Benner A, Döhner H, Wiessler M, and Lyko F (2003) Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 31:E2.
34. Tanaka A, Nishida K, Okuda H, Nishiura T, Higashi Y, Fujimoto S, and Nagasawa K (2011) Peroxynitrite treatment reduces adenosine uptake via the equilibrative nucleoside transporter in rat astrocytes. Neurosci Lett 498: 52-56.
35. Visser F, Zhang J, Raborn RT, Baldwin SA, Young JD, and Cass CE (2005) Residue 33 of human equilibrative nucleoside transporter 2 is a functionally important component of both the dipyridamole and nucleoside binding sites. Mol Pharmacol 67: 1291-1298.
36. Ward JL and Tse CM (1999) Nucleoside transport in human colonic epithelial cell lines: evidence for two Na1-independent transport systems in T84 and Caco-2 cells. Biochim Biophys Acta 1419: 15-22.
37. Zhang J, Visser F, King KM, Baldwin SA, Young JD, and Cass CE (2007) The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 26: 85-110.
38. Zimmerman EI, Huang M, Leisewitz AV, Wang Y, Yang J, and Graves LM (2009) Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells. FEBS Lett 583: 425-429.